A three-year analysis of SURMOUNT-1 found that tirzepatide was associated with lower predicted cardiovascular risk than placebo in adults with overweight or obesity and prediabetes. At 176 weeks, the 15 mg tirzepatide group had a modeled 1.31-percentage-point reduction in 10-year cardiovascular risk from baseline, while the placebo group had a modeled 3.84-percentage-point increase. The modeled hazard ratio was 0.62.
The result is encouraging, but it does not prove that tirzepatide prevents heart attacks, strokes, or cardiovascular death. The analysis was post hoc and used the Framingham Heart Study equation to estimate future risk from clinical risk factors. A dedicated event-based cardiovascular-outcomes trial is still needed to determine whether the predicted improvement translates into fewer cardiovascular events.
The findings, published online on August 10, 2026, add to the evidence surrounding tirzepatide and long-term cardiometabolic health. The analysis asks an important question: whether the weight loss and metabolic changes observed during obesity treatment are associated with a more favorable cardiovascular-risk profile in people who may not yet have established cardiovascular disease.
What the new tirzepatide cardiovascular-risk analysis found
The analysis used data from SURMOUNT-1, a phase 3 randomized trial that evaluated tirzepatide in adults with obesity or overweight. Participants did not have diabetes at enrollment and were assigned to tirzepatide at 5 mg, 10 mg, or 15 mg, or to placebo, during the 176-week study period.
The new analysis focused on participants with obesity or overweight and prediabetes. Researchers calculated estimated 10-year cardiovascular risk with the Framingham Heart Study equation. The model incorporates established variables such as age, sex, blood pressure, cholesterol, smoking status, and diabetes-related factors.
Among the broader SURMOUNT-1 population, 1,032 participants had prediabetes and 976 did not have pre-existing cardiovascular disease. The modeled analysis included 962 participants who had a baseline risk score and at least one follow-up score. These figures describe related but not necessarily identical analysis populations.
The strongest modeled result appeared in the 15 mg group:
| Time point | Tirzepatide 15 mg | Placebo | Reported interpretation |
|---|---|---|---|
| 72 weeks | 1.92-percentage-point absolute reduction in predicted 10-year risk | 1.10-percentage-point absolute increase | Modeled hazard ratio: 0.73 |
| 176 weeks | 1.31-percentage-point absolute reduction | 3.84-percentage-point absolute increase | Modeled hazard ratio: 0.62 |
In the context of the model, the findings indicate a more favorable cardiovascular-risk trajectory with tirzepatide than with placebo. The placebo group’s modeled risk increased over time, while predicted risk in the tirzepatide group declined from baseline.
Those values should not be interpreted as a direct count of prevented cardiovascular events. SURMOUNT-1 was not designed primarily to detect differences in adjudicated heart attacks, strokes, or cardiovascular deaths, and the new analysis was not an event-driven cardiovascular-outcomes trial.
Why predicted cardiovascular risk is useful but not definitive
Risk models are used in preventive medicine to combine several clinical measurements into an estimate of future cardiovascular disease. When a treatment improves multiple risk factors at the same time, a model can show how the overall estimated risk profile changes over follow-up.
Tirzepatide can affect several inputs used in cardiovascular-risk calculations. In obesity research, treatment has been associated with lower body weight, improved glycemic measures, reduced waist circumference, lower blood pressure, and changes in some lipid measurements. These factors are relevant because excess adiposity, hyperglycemia, hypertension, and dyslipidemia are associated with cardiovascular disease.
The value of the SURMOUNT-1 analysis is its duration. The 176-week time point offers a view of modeled risk after approximately three years rather than only during an early weight-loss period. Long-term follow-up is particularly relevant to obesity research because cardiovascular prevention depends on whether risk-factor improvements persist during ongoing treatment.
Even so, a risk equation is not a substitute for an event-based trial. A modeled reduction may overestimate or underestimate the eventual clinical effect. Risk equations can also omit biological effects that are not represented by their inputs, including possible changes in vascular inflammation, kidney function, thrombosis, or cardiac remodeling.
The researchers also examined whether the Framingham model could predict the treatment effect observed in the REWIND trial of dulaglutide. They reported that the modeled hazard ratio was consistent with the hazard ratio based on observed cardiovascular events in that separate study. That comparison supports the model’s research utility, but it does not turn the SURMOUNT-1 analysis into a cardiovascular-outcomes trial.
What the analysis does and does not show
What it supports
- Tirzepatide was associated with lower predicted 10-year cardiovascular risk than placebo in the analyzed population.
- The favorable modeled trajectory continued through 176 weeks.
- The findings are consistent with the possibility that weight loss and metabolic improvements can produce a more favorable overall cardiovascular-risk profile.
- The analysis supports further study of tirzepatide in formal cardiovascular primary-prevention research.
What it does not establish
- It does not prove that tirzepatide prevents heart attacks.
- It does not prove that tirzepatide prevents ischemic or hemorrhagic stroke.
- It does not prove a reduction in cardiovascular death.
- It does not show that tirzepatide is superior to semaglutide or another <a href="https://glp1place.com/tools/compound/glp-1/”>GLP-1 receptor agonist for cardiovascular protection.
- It does not establish a new cardiovascular indication for people without established cardiovascular disease.
The distinction matters because cardiovascular claims require carefully designed trials with prospectively defined endpoints, event adjudication, appropriate comparators, and sufficient follow-up. A post hoc risk-model analysis can provide supportive evidence, but it cannot answer every clinical question.
How this fits with other tirzepatide cardiovascular evidence
The SURMOUNT-1 analysis is one part of a broader cardiovascular evidence base that remains incomplete.
SURPASS-CVOT compared tirzepatide directly with dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease. The trial was designed to assess whether tirzepatide was noninferior to dulaglutide for major adverse cardiovascular events. Its findings supported noninferiority, but did not establish superiority over dulaglutide.
The SURPASS-CVOT and SURMOUNT-1 populations and research questions differ. SURPASS-CVOT studied people with diabetes and established cardiovascular disease. SURMOUNT-1 enrolled people with obesity or overweight without diabetes, while this analysis focused on participants with prediabetes and modeled primary-prevention risk. One trial examined comparative cardiovascular outcomes in a higher-risk population; the other examined predicted risk before a documented cardiovascular event.
A systematic review and meta-analysis also shows why the question remains unsettled. The review compared tirzepatide with GLP-1 receptor agonists across randomized and observational studies involving more than 323,000 patients. It did not find a statistically significant reduction in major adverse cardiovascular events compared with GLP-1 receptor agonists and reported substantial heterogeneity between studies. This does not establish that tirzepatide lacks cardiovascular benefit. It indicates that the available comparative evidence is not yet sufficiently consistent to support a definitive claim that tirzepatide is better than the broader GLP-1 receptor agonist class for cardiovascular outcomes.
For context on head-to-head weight loss rather than cardiovascular outcomes, GLP1Place previously covered the SURMOUNT-5 comparison of tirzepatide and semaglutide in our analysis of the SURMOUNT-5 trial. That trial reported greater average weight loss with tirzepatide, but its findings should not automatically be converted into a claim of superior cardiovascular protection.
Why obesity and prediabetes are important cardiovascular settings
Obesity and prediabetes are associated with a group of physiologic changes that can increase cardiovascular risk. These include insulin resistance, hypertension, abnormal lipid metabolism, chronic low-grade inflammation, endothelial dysfunction, sleep-disordered breathing, and progressive vascular injury.
People with obesity and prediabetes may have elevated cardiovascular risk before diabetes or a documented cardiovascular event develops. That makes primary prevention an important research target. A treatment that produces durable changes in body weight, glucose regulation, blood pressure, and lipid patterns could potentially delay the transition from risk factors to clinical disease.
The analysis is relevant because many cardiovascular-outcomes trials enroll people who already have established disease. Such populations have higher event rates and can allow trials to reach statistical conclusions more efficiently. However, the public-health effect of obesity treatment may also depend on preventing first cardiovascular events in people who have not yet experienced a heart attack or stroke.
A lower predicted risk does not necessarily equal a lower absolute number of events for every individual. Absolute risk depends on baseline characteristics, age, prior disease, smoking, blood pressure, cholesterol, kidney function, and other factors. The modeled average from this study should not be applied directly to every person with obesity or prediabetes.
Industry Impact
The findings may influence how researchers evaluate next-generation incretin therapies. Tirzepatide is already an important benchmark in weight-loss and glycemic-control research. Evidence suggesting a durable cardiovascular-risk association could broaden research interest from weight management to long-term cardiometabolic prevention.
The analysis also highlights the importance of including cardiovascular endpoints in future obesity-drug programs. Weight loss remains a central efficacy outcome, but researchers, regulators, clinicians, payers, and health systems increasingly seek evidence about outcomes beyond body weight.
Future programs may therefore examine blood pressure, lipid fractions, glycemic status, kidney markers, inflammation, liver disease, sleep apnea, physical function, and body composition alongside weight change. Weight loss alone does not fully describe cardiovascular benefit.
The duration of the analysis is another relevant feature. Approximately three years of data is longer than the follow-up in many obesity studies. That makes long-term observation important, because early improvements may not persist if treatment is discontinued, adherence changes, or weight is regained. Chronic-disease research requires evidence that potential benefits remain present over clinically meaningful periods.
Regulatory and compliance context
The August 10, 2026 paper is a research finding, not a new regulatory approval or expanded indication. It does not authorize off-label use, establish a new prescribing pathway, or prove that tirzepatide prevents cardiovascular events in people without established disease.
Any future cardiovascular claim would require appropriate regulatory review based on the totality of evidence. Risk-model analyses can contribute to that evidence, but predicted outcomes and direct clinical outcomes remain distinct categories.
The study also illustrates why research claims should be phrased precisely. “Lower predicted cardiovascular risk” is not interchangeable with “fewer heart attacks.” “Associated with” is not interchangeable with “caused.” An analysis of tirzepatide versus placebo is not evidence that tirzepatide is superior to semaglutide, dulaglutide, or another active comparator.
For readers evaluating research, the key details are the study design, population, endpoint, comparator, follow-up period, and whether the outcome was directly measured. GLP1Place’s guide to reading GLP-1 clinical trials provides additional background on these distinctions.
Market Forecast
Cardiovascular evidence is likely to become increasingly important in obesity medicine. If future event-based trials confirm that tirzepatide reduces heart attacks, strokes, or cardiovascular death, the treatment could become more firmly integrated into preventive cardiometabolic care rather than being viewed primarily through the lens of weight management.
Such evidence could affect payer decisions, treatment guidelines, and how health systems evaluate the long-term benefits and tolerability of obesity medicines. It could also increase pressure on newer therapies to demonstrate meaningful outcomes beyond weight loss.
The near-term significance of this analysis should nevertheless be viewed as incremental rather than definitive. The findings are encouraging, but they are based on modeled risk and are connected to the existing SURMOUNT-1 program. More direct evidence is expected from event-based studies such as SURMOUNT-MMO and from analyses conducted across different populations.
The evidence can be viewed in several broad tiers:
| Evidence tier | What it demonstrates | Current relevance |
|---|---|---|
| Weight-loss trials | Changes in body weight and related metabolic measures | Strong evidence for tirzepatide and other incretin therapies |
| Risk-model analyses | Projected changes in future cardiovascular risk | Encouraging but indirect |
| Comparative cardiovascular trials | Relative outcomes versus an active comparator | Useful for noninferiority and comparative safety |
| Placebo-controlled event trials | Direct evidence of cardiovascular-event differences | Most informative for prevention claims |
Researcher Takeaways
- The analysis provides three-year evidence that tirzepatide was associated with lower predicted cardiovascular risk in adults with obesity or overweight and prediabetes.
- The 15 mg group had a modeled hazard ratio of 0.62 at 176 weeks compared with placebo.
- The result came from a risk equation rather than a trial designed primarily to count cardiovascular events.
- The findings are most relevant to modeled primary-prevention risk and should not automatically be generalized to people with established cardiovascular disease.
- The analysis does not establish superiority over semaglutide or another GLP-1 receptor agonist.
- Event-based trials remain necessary to determine whether modeled risk reductions translate into fewer heart attacks, strokes, or cardiovascular deaths.
The post hoc population was smaller than the full SURMOUNT-1 cohort because participants needed the measurements required to calculate risk at baseline and follow-up. Missing data, selection effects, and assumptions built into the Framingham equation can influence the result.
At the same time, the consistent direction of the modeled effect across time points is notable. The finding was not limited to a short-term weight-loss phase; predicted risk remained more favorable at 176 weeks. That durability is one reason the analysis merits attention even though it does not provide a final cardiovascular verdict.
Consumer Awareness Notes
Readers should not interpret the analysis as proof that tirzepatide is appropriate for every person with obesity, prediabetes, or cardiovascular risk. Research findings do not replace an individualized evaluation by a qualified healthcare professional.
The study also does not support combining tirzepatide with other incretin medicines, using unapproved products, selecting a dose, or treating the findings as instructions for self-directed use. Research about a prescription medicine should be read as evidence about a study population and protocol, not as personal treatment guidance.
People evaluating the cardiovascular implications of obesity medicines should distinguish between three questions: whether a drug causes weight loss, whether it improves cardiovascular risk factors, and whether it prevents cardiovascular events. Tirzepatide has substantial evidence for weight loss, growing evidence for improvements in risk factors, and an evolving evidence base for direct cardiovascular outcomes.
For broader context on lean mass and body-composition outcomes during incretin treatment, see GLP1Place’s coverage of the EMBRAZE tirzepatide and apitegromab trial. Body composition is not identical to cardiovascular risk, but it is part of the broader question of what long-term obesity treatment changes inside the body.
FAQ
Does tirzepatide reduce cardiovascular risk?
A 2026 post hoc analysis of SURMOUNT-1 found that tirzepatide was associated with lower predicted 10-year cardiovascular risk than placebo after three years in adults with overweight or obesity and prediabetes. Because the study used a risk model rather than directly counting cardiovascular events, it does not yet prove that tirzepatide prevents heart attacks or strokes.
What did the new SURMOUNT-1 cardiovascular analysis find?
At 176 weeks, the 15 mg tirzepatide group had a 1.31-percentage-point reduction in predicted 10-year cardiovascular risk from baseline, while the placebo group had a 3.84-percentage-point increase. The modeled hazard ratio was 0.62.
Was the SURMOUNT-1 analysis a cardiovascular-outcomes trial?
No. SURMOUNT-1 was an obesity and weight-management trial. The new analysis calculated predicted cardiovascular risk using the Framingham Heart Study equation rather than being designed to detect differences in heart attacks, strokes, or cardiovascular deaths.
Who was included in the tirzepatide cardiovascular analysis?
The analysis focused on participants with obesity or overweight and prediabetes from SURMOUNT-1. Of the broader study population, 962 participants had the baseline and follow-up measurements needed for the modeled analysis. Related population counts, including participants without pre-existing cardiovascular disease, describe overlapping study subsets.
What is the SURMOUNT-MMO trial?
SURMOUNT-MMO is an event-based cardiovascular-outcomes trial designed to test whether tirzepatide reduces major cardiovascular events in people with obesity or overweight who have established cardiovascular disease or elevated cardiovascular risk. Its results are intended to provide more direct evidence than a risk-model analysis.
Can this study prove tirzepatide prevents heart attacks?
No. The study provides supportive evidence because tirzepatide improved several cardiovascular risk factors and lowered modeled risk. A trial that prospectively measures adjudicated cardiovascular events is needed to establish whether tirzepatide prevents heart attacks, strokes, or cardiovascular death.
How does this differ from the SURPASS-CVOT results?
SURPASS-CVOT compared tirzepatide with dulaglutide in adults with type 2 diabetes and established cardiovascular disease and found tirzepatide to be noninferior for major cardiovascular events. The SURMOUNT-1 analysis examined predicted primary-prevention risk in adults with obesity or overweight and prediabetes, so the populations and research questions are different.
Does the analysis show tirzepatide is better than semaglutide for cardiovascular protection?
No. The analysis did not directly compare tirzepatide with semaglutide and was not designed to establish superiority over another GLP-1 receptor agonist. Cross-trial comparisons should not be treated as head-to-head evidence.
Bottom line: The three-year SURMOUNT-1 analysis strengthens the evidence that tirzepatide may improve the cardiovascular-risk profile of adults with obesity or prediabetes. However, the central unanswered question is whether those modeled improvements become fewer real cardiovascular events. That answer will require dedicated outcomes trials rather than extrapolation from weight loss or risk equations alone.
Author: GLP1Place Research Team
Primary research: European Journal of Preventive Cardiology analysis of SURMOUNT-1; Diabetes, Obesity and Metabolism systematic review of tirzepatide cardiovascular outcomes; NEJM SURPASS-CVOT trial.